首页> 外文OA文献 >The Safety and Efficacy of Colchicine for the Treatment of Pericarditis
【2h】

The Safety and Efficacy of Colchicine for the Treatment of Pericarditis

机译:秋水仙碱治疗心包炎的安全性和有效性

摘要

BACKGROUND: Colchicine has been traditionally used for the treatment of gout. In just over the last twenty years, colchicine has been gaining interest as a treatment for acute and recurrent pericarditis. A few small studies have addressed the safety and efficacy of this treatment, however, a general agreement has not been reached.METHODS: A systematic literature review of the studies focusing on colchicine for the treatment of pericarditis, from 1990 to present, was performed using the MEDLINE, CINAHL and Web of Science databases. A modified validity scoring method (0-10) was applied to the studies that qualified through the inclusion and exclusion criteria.RESULTS: Five studies that focused on colchicine for the treatment of pericarditis met the inclusion and exclusion criteria. There were two randomized, open-label studies (n=120 u26 n=84) with a validity score of eight. There was one prospective, cohort study (n=58) with a validity score of five. There was one retrospective, multi-center case analysis (n=119) that received a validity score of two, and a prospective case series (n=9) with a validity score of three. All of the studies found colchicine to be effective for the treatment of acute or recurrent pericarditis, with 1 mg daily as the most common dose. There were no reports of serious, adverse reactions to colchicine. Diarrhea was the most common side effect. As a secondary outcome, corticosteroids were found to be an independent risk factor for the recurrence of pericarditis in three of the studies.CONCLUSION: Based on this systematic review of literature, there is moderate evidence showing colchicine to be safe and effective in the treatment of acute or recurrent pericarditis. However, a larger, double-blinded, randomized-controlled trial is needed to further investigate this potential treatment. There is also some evidence to support corticosteroids as an independent risk factor for the recurrence of pericarditis.
机译:背景:秋水仙碱传统上已用于治疗痛风。在过去的二十年中,秋水仙碱作为急性和复发性心包炎的治疗方法已引起人们的兴趣。几项小型研究已经探讨了这种治疗方法的安全性和有效性,但尚未达成普遍共识。方法:1990年至今,针对秋水仙碱治疗心包炎的研究进行了系统的文献综述。 MEDLINE,CINAHL和Web of Science数据库。结果:通过秋水仙碱治疗心包炎的五项研究符合纳入和排除标准,将改良的有效性评分方法(0-10)用于符合纳入和排除标准的研究。有两项随机,开放标签研究(n = 120 u26 n = 84),有效评分为8。有一项前瞻性队列研究(n = 58),有效性得分为5。一项回顾性,多中心案例分析(n = 119)的有效评分为2,而一个前瞻性病例系列(n = 9)的有效性评分为3。所有研究均发现秋水仙碱可有效治疗急性或复发性心包炎,最常见剂量为每天1毫克。没有关于秋水仙碱的严重不良反应的报道。腹泻是最常见的副作用。作为次要结果,在三项研究中发现皮质类固醇是心包炎复发的独立危险因素。结论:根据文献的系统综述,有中等证据表明秋水仙碱可安全有效地治疗心包炎急性或复发性心包炎。但是,需要更大的双盲,随机对照试验来进一步研究这种潜在的治疗方法。也有一些证据支持皮质类固醇作为心包炎复发的独立危险因素。

著录项

  • 作者

    Murray Scott;

  • 作者单位
  • 年度 2009
  • 总页数
  • 原文格式 PDF
  • 正文语种
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号